Trial Profile
The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DOMONO
- 07 Mar 2018 This study was discontinued prematurely due to an unforeseen number of virological failures with acquired resistance in integrase in 3 patients, according results presented at the 25th Conference on Retroviruses and Opportunistic Infections.
- 07 Mar 2018 Results (n=85) assessing renal, bone, lipid and inflammatory markers before and after a switch from TDF-containing cART to dolutegravir monotherapy in this study, presented at the 25th Conference on Retroviruses and Opportunistic Infections.
- 27 Oct 2017 Results (n=10) presented at the 16th European AIDS Conference.